BCR and neoplasm: We acknowledge some limitations of our study: the restricted number of patients examined; the absence of matched tumor samples to assess the BCR repertoire in situ; relying on the VH sequence for target recognition, only; the reconstruction of some antibodies in a murine/human hybrid format that could have impaired the original binding function of the fully human counterparts, and the unknown nature of the antigens bound.